Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 335.98 | 285.77 | 465.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.28) | (9.23) | (6.09) | (9.43) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 33.98 | 33.11 | 243.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.49) | (0.25) | (0.22) | (1.41) | |
EV/FCF |
(0.38) | (0.26) | (0.22) | (1.41) | |
Quick Ratio |
9.39 | 8.82 | 8.71 | 8.04 | |
Current Ratio |
10.32 | 9.13 | 9.06 | 8.36 | |
Net Debt/EBITDA |
7.37 | 6.20 | 5.20 | 3.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.61 | 1.69 | 2.08 | 1.42 | |
Capex/Depreciation |
(3.11) | 6.78 | (2.28) | (2.28) | |
Interest Coverage |
(19,269.50) | (45,371.00) | (2,995.53) | (48,373.00) | |
Research and Development Expense of Revenue |
12,359.91% | 15,180.89% | 14,974.34% | 24,063.33% | |
Selling, General and Administrative Expense of Revenue |
5,500.00% | 5,084.00% | 5,007.52% | 8,285.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3,076.50% | 2,534.67% | 2,188.05% | 3,729.33% | |
Graham Net Nets |
(3.24) | (3.55) | (4.26) | (2.48) | |
Graham Number |
9.61 | 9.40 | 9.27 | 7.66 | |
Earnings Yield |
(22.73%) | (23.21%) | (29.61%) | (26.96%) | |
Free Cash Flow Yield |
(44.91%) | (39.03%) | (51.90%) | (37.18%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.24) | (0.29) | (0.22) | |
Capex per Share |
(0.04) | 0.09 | (0.03) | (0.02) | |
Free Cash Flow per Share |
(0.24) | (0.15) | (0.32) | (0.24) | |
Cash per Share |
2.01 | 2.02 | 1.58 | 0.97 | |
Shareholders Equity per Share |
(7.47) | (7.55) | (7.21) | (4.74) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(7.47) | (7.55) | (7.21) | (4.74) | |
Free Cash Flow |
(31.79) | (20.05) | (45.47) | (44.21) | |
Working Capital |
270.93 | 249.94 | 208.97 | 167.06 | |
Capital Expenditures |
(5.20) | 12.46 | (3.78) | (3.83) | |
Net Current Asset Value |
(1,059.64) | (1,066.09) | (1,081.66) | (942.78) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
23.95 | (55.39) | 16.75 | 25.55 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.17 | 1.79 | 1.39 | 1.37 | |
Average Payables |
2.40 | 2.29 | 2.86 | 2.03 | |
Average Assets |
413.20 | 388.32 | 349.42 | 310.57 | |
Average Common Equity |
(993.87) | (1,003.08) | (1,011.17) | (943.02) |
Columns are period end dates